Close Menu

NEW YORK – Oncocyte said Thursday that it has reached agreements for select institutional investors and other parties to purchase an aggregate of about 5.1 million shares of the company’s common stock at $1.70 per share.

Net proceeds from the financing, which will close no later than November 15, are expected to be about $8.5 million, OncoCyte wrote in a document filed with the US Securities and Exchange commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.